van Hoof H J, de Sévaux R G, van Baelen H, Swinkels L M, Klipping C, Ross H A, Sweep C G
Department of Chemical Endocrinology, University Hospital Nijmengen, Nijmegen, The Netherlands.
Eur J Endocrinol. 2001 Apr;144(4):391-6. doi: 10.1530/eje.0.1440391.
A novel assay was employed to study the free 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations in various populations with different levels of 1,25(OH)2D and vitamin D binding protein (DBP).
In 12 healthy women before and after 3 months of oral estrogen/progestagen treatment, 10 pregnant women, and 16 patients with a nephrotic syndrome and normal renal function, the concentrations of total and free 1,25(OH)2D, DBP and albumin were assessed.
The total concentration of 1,25(OH)2D in serum was assessed using a radioreceptor assay. The free fraction of 1,25(OH)2D was measured using symmetric dialysis. DBP was assessed using single radial immunodiffusion. Serum albumin concentrations were measured on an automated analyzer.
In healthy women, the concentrations of total 1,25(OH)2D, free 1,25(OH)2D and DBP were 132+/-19 pmol/l, 92+/-30 fmol/l and 5.59+/-0.43 micromol/l. After 3 months of estrogen/progestagen treatment, total 1,25(OH)2D and DBP levels rose significantly to 175+/-51 pmol/l and 8.32+/-1.59 micromol/l (P< or =0.05 and P< or =0.001); the free 1,25(OH)2D remained unchanged (105+/-39 fmol/l; not significant). Pregnant women had significantly higher levels of total 1,25(OH)2D and DBP (239+/-68 pmol/l and 11.32+/-1.77 micromol/l; both P</=0.001); the free 1,25(OH)2D level, however, was not different (104+/-27 fmol/l; not significant). Unexpectedly, in patients with nephrotic syndrome, no lower DBP levels were found (5.36+/-0.84 micromol/l) relative to that in controls. Despite this, levels of both total (69+/-26 pmol/l, P< or =0.001) and free 1,25(OH)2D (53+/-28 fmol/l; P< or =0.001) were significantly lower than in controls. Albumin levels were lowered from 628+/-38 micromol/l to 300+/-84 micromol/l (P < or = 0.001).
Higher estrogen levels result in higher DBP levels, with a parallel rise in total 1,25(OH)2D levels but without a change in the biologically active free fraction. The results in patients with nephrotic syndrome show that, with increasing glomerular protein leakage, the free 1,25(OH)2D concentration cannot be maintained.
采用一种新型检测方法研究不同1,25 - 二羟基维生素D(1,25(OH)₂D)和维生素D结合蛋白(DBP)水平的各类人群中游离1,25(OH)₂D的浓度。
对12名接受3个月口服雌激素/孕激素治疗前后的健康女性、10名孕妇以及16名肾功能正常的肾病综合征患者,评估其总1,25(OH)₂D、游离1,25(OH)₂D、DBP和白蛋白的浓度。
采用放射受体分析法评估血清中1,25(OH)₂D的总浓度。使用对称透析法测量1,25(OH)₂D的游离部分。采用单向放射免疫扩散法评估DBP。在自动分析仪上测量血清白蛋白浓度。
健康女性中,总1,25(OH)₂D、游离1,25(OH)₂D和DBP的浓度分别为132±19 pmol/L、92±30 fmol/L和5.59±0.43 μmol/L。雌激素/孕激素治疗3个月后,总1,25(OH)₂D和DBP水平显著升高至175±51 pmol/L和8.32±1.59 μmol/L(P≤0.05和P≤0.001);游离1,25(OH)₂D保持不变(105±39 fmol/L;无显著差异)。孕妇的总1,25(OH)₂D和DBP水平显著更高(分别为239±68 pmol/L和11.32±1.77 μmol/L;均P≤0.001);然而,游离1,25(OH)₂D水平无差异(104±27 fmol/L;无显著差异)。出乎意料的是,肾病综合征患者的DBP水平相对于对照组并未降低(5.36±0.84 μmol/L)。尽管如此,总1,(69±26 pmol/L,P≤0.001)和游离1,25(OH)₂D(53±28 fmol/L;P≤0.001)水平均显著低于对照组。白蛋白水平从628±38 μmol/L降至300±84 μmol/L(P≤0.001)。
较高的雌激素水平导致DBP水平升高,总1,25(OH)₂D水平随之平行升高,但生物活性游离部分无变化。肾病综合征患者的结果表明,随着肾小球蛋白漏出增加,游离1,25(OH)₂D浓度无法维持。